Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A US perspective on closing the carbon cycle to defossilize difficult-to-electrify segments of our economy.
Shaw WJ, Kidder MK, Bare SR, Delferro M, Morris JR, Toma FM, Senanayake SD, Autrey T, Biddinger EJ, Boettcher S, Bowden ME, Britt PF, Brown RC, Bullock RM, Chen JG, Daniel C, Dorhout PK, Efroymson RA, Gaffney KJ, Gagliardi L, Harper AS, Heldebrant DJ, Luca OR, Lyubovsky M, Male JL, Miller DJ, Prozorov T, Rallo R, Rana R, Rioux RM, Sadow AD, Schaidle JA, Schulte LA, Tarpeh WA, Vlachos DG, Vogt BD, Weber RS, Yang JY, Arenholz E, Helms BA, Huang W, Jordahl JL, Karakaya C, Kian KC, Kothandaraman J, Lercher J, Liu P, Malhotra D, Mueller KT, O'Brien CP, Palomino RM, Qi L, Rodriguez JA, Rousseau R, Russell JC, Sarazen ML, Sholl DS, Smith EA, Stevens MB, Surendranath Y, Tassone CJ, Tran B, Tumas W, Walton KS. Shaw WJ, et al. Among authors: boettcher s. Nat Rev Chem. 2024 May;8(5):376-400. doi: 10.1038/s41570-024-00587-1. Epub 2024 May 1. Nat Rev Chem. 2024. PMID: 38693313 Review.
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells.
Mueller J, Schimmer RR, Koch C, Schneiter F, Fullin J, Lysenko V, Pellegrino C, Klemm N, Russkamp N, Myburgh R, Volta L, Theocharides AP, Kurppa KJ, Ebert BL, Schroeder T, Manz MG, Boettcher S. Mueller J, et al. Among authors: boettcher s. EMBO Mol Med. 2024 Mar;16(3):445-474. doi: 10.1038/s44321-024-00024-2. Epub 2024 Feb 14. EMBO Mol Med. 2024. PMID: 38355749 Free PMC article.
Shifting attention between perception and working memory.
Gresch D, Boettcher SEP, van Ede F, Nobre AC. Gresch D, et al. Among authors: boettcher sep. Cognition. 2024 Apr;245:105731. doi: 10.1016/j.cognition.2024.105731. Epub 2024 Jan 25. Cognition. 2024. PMID: 38278040 Free article.
Terms of debate: Consensus definitions to guide the scientific discourse on visual distraction.
Liesefeld HR, Lamy D, Gaspelin N, Geng JJ, Kerzel D, Schall JD, Allen HA, Anderson BA, Boettcher S, Busch NA, Carlisle NB, Colonius H, Draschkow D, Egeth H, Leber AB, Müller HJ, Röer JP, Schubö A, Slagter HA, Theeuwes J, Wolfe J. Liesefeld HR, et al. Among authors: boettcher s. Atten Percept Psychophys. 2024 Jan 4. doi: 10.3758/s13414-023-02820-3. Online ahead of print. Atten Percept Psychophys. 2024. PMID: 38177944 Review.
Circulating senescent myeloid cells infiltrate the brain and cause neurodegeneration in histiocytic disorders.
Wilk CM, Cathomas F, Török O, Le Berichel J, Park MD, Bigenwald C, Heaton GR, Hamon P, Troncoso L, Scull BP, Dangoor D, Silvin A, Fleischmann R, Belabed M, Lin H, Merad Taouli E, Boettcher S, Li L, Aubry A, Manz MG, Kofler JK, Yue Z, Lira SA, Ginhoux F, Crary JF, McClain KL, Picarsic JL, Russo SJ, Allen CE, Merad M. Wilk CM, et al. Among authors: boettcher s. Immunity. 2023 Dec 12;56(12):2790-2802.e6. doi: 10.1016/j.immuni.2023.11.011. Immunity. 2023. PMID: 38091952
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.
Al-Sawaf O, Ligtvoet R, Robrecht S, Stumpf J, Fink AM, Tausch E, Schneider C, Boettcher S, Mikusko M, Ritgen M, Schetelig J, von Tresckow J, Vehling-Kaiser U, Gaska T, Wendtner CM, Chapuy B, Fischer K, Kreuzer KA, Stilgenbauer S, Staber P, Niemann C, Hallek M, Eichhorst B. Al-Sawaf O, et al. Among authors: boettcher s. Nat Med. 2024 Jan;30(1):240-248. doi: 10.1038/s41591-023-02722-9. Epub 2023 Dec 9. Nat Med. 2024. PMID: 38071379 Free PMC article. Clinical Trial.
Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias.
Nishida Y, Ishizawa J, Ayoub E, Montoya RH, Ostermann LB, Muftuoglu M, Ruvolo VR, Patsilevas T, Scruggs DA, Khazaei S, Mak PY, Tao W, Carter BZ, Boettcher S, Ebert BL, Daver NG, Konopleva M, Seki T, Kojima K, Andreeff M. Nishida Y, et al. Among authors: boettcher s. Sci Adv. 2023 Dec;9(48):eadh1436. doi: 10.1126/sciadv.adh1436. Epub 2023 Nov 29. Sci Adv. 2023. PMID: 38019903 Free PMC article.
197 results